Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias

Lancet Oncology

Volumn 4, Issue 2, 2003, Pages 75-85

  Gambacorti Passerini, Carlo B ^a   Gunby, Rosalind H ^a   Piazza, Rocco ^a   Galietta, Annamaria ^a   Rostagno, Roberta ^a   Scapozza, Leonardo ^b  

^a National Tumour Institute   (Italy)

^b ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CLINDAMYCIN; CYTARABINE; ERYTHROMYCIN; HYDROXYUREA; IMATINIB; INTERFERON; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER RESEARCH; CYTOGENETICS; DATA ANALYSIS; DERMATOFIBROSARCOMA PROTUBERANS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HYPEREOSINOPHILIA; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; SIDE EFFECT;

EID: 0037315281     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)00979-3     Document Type: Review

References (61)

1. JM Goldman BJ Druker Chronic myeloid leukemia: current treatment options Blood 98 2001 2039 2042
2. E Buchdunger J Zimmermann H Mett Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative Cancer Res 56 1996 100 104
3. J Zimmermann E Buchdunger H Mett Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives Bioorg Med Chem Lett 7 1997 187 192
4. K Okuda E Weisberg DG Gilliland JD Griffin ARG tyrosine kinase activity is inhibited by STI571 Blood 97 2001 2440 2448
5. J Konopa S Watanabe O Witte An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity Cell 37 1984 1035 1042
6. H Pluk K Dorey G Superti-Furga Autoinhibition of c-Abl Cell 108 2002 247 259
7. H Kantarjian JV Melo S Tura Chronic myelogenous leukemia: disease biology and current and future therapeutic strategies Hematology (Am Soc Hematol Educ Program) 2000 90 109
8. MJ Mauro M O'Dwyer MC Heinrich BJ Druker STI571: a paradigm of new agents for cancer therapeutics J Clin Oncol 20 2002 325 334
9. BJ Druker S Tamura E Buchdunger Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 1996 561 566
10. C Gambacorti-Passerini P le Coutre L Mologni Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis Blood Cells Mol Dis 23 1997 380 394
11. MW Deininger JM Goldman N Lydon JV Melo The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells Blood 90 1997 3691 3698
12. P le Coutre L Mologni L Cleris In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor J Natl Cancer Inst 91 1999 163 168
13. T Schindler W Bornmann P Pellicena Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
14. OG Ottmann BJ Druker CL Sawyers A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias Blood 100 2002 1965 1971
15. CL Sawyers A Hochhaus E Feldman Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 2002 3530 3539
16. M Talpaz RT Silver BJ Druker Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 2002 1928 1937
17. H Kantarjian C Sawyers A Hochhaus Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
18. B Druker STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of a randomized study Proc Am Soc Clin Oncol 20 2002 (abstr 1)
19. MK Magnusson KE Meade R Nakamura Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene Blood 100 2002 1088 1091
20. JF Apperley M Gardembas JV Melo Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta N Engl J Med 347 2002 481 487
21. AT van Oosterom I Judson J Verweij Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Lancet 358 2001 1421 1423
22. GD Demetri M von Mehren CD Blanke Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Eng J Med 347 2002 472 480
23. MC Heinrich CD Blanke BJ Druker CL Corless Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J Clin Oncol 20 2002 1692 1703
24. JL Schaller GA Burkland Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate Med Gen Med 3 2001 9
25. GJ Gleich KM Leiferman A Pardanani Treatment of hypereosinophilic syndrome with imatinib mesilate Lancet 359 2002 1577 1578
26. RG Maki RA Awan RH Dixon Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans Int J Cancer 100 2002 623 626
27. BP Rubin SM Schuetze JF Eary Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans J Clin Oncol 20 2002 3586 3591
28. C Gambacorti-Passerini S Bungaro G Cazzaniga BCR-ABL gene amplification causes reversible cytogenetic relapse and resistance to imatinib (STI571) in a chronic phase CML patients Blood 100 2002 216a (abstr 4376).
29. BJ Druker M Talpaz DJ Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 2001 1031 1037
30. C Gambacorti-Passerini F Rossi M Verga Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients Blood Cells Mol Dis 28 2002 361 372
31. ME Gorre NP Shah K Ellwood Roots of clinical resistance to STI-571 cancer therapy Science 293 2001 2163 (abstr).
32. P le Coutre E Tassi M Varella-Garcia Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758 1766
33. E Weisberg JD Griffin Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines Blood 95 2000 3498 3505
34. FX Mahon MW Deininger B Schultheis Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2000 1070 1079
35. ME Gorre M Mohammed K Ellwood Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
36. S Branford Z Rudzki S Walsh High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2002 3472 3475
37. WK Hofmann S de Vos D Elashoff Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 359 2002 481 486
38. S Kreil C Muller T Lahaye Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy Blood 98 2001 435a (abstr 1823).
39. AJ Tipping FX Mahon V Lagarde Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells Blood 98 2001 3864 3867
40. B Nagar WG Bornmann P Pellicena Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 2002 4236 4243
41. N von Bubnoff F Schneller C Peschel J Duyster BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 359 2002 487 491
42. NP Shah JM Nicoll ME Gorre Resistance to Gleevec: sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired- and de novo- resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis Blood 98 2001 3205 (abstr 770).
43. C Barthe P Cony-Makhoul JV Melo JR Mahon Roots of clinical resistance to STI-571 cancer therapy Science 293 2001 2163
44. A Hochhaus S Kreil A Corbin Roots of clinical resistance to STI-571 cancer therapy Science 293 2001 2163
45. C Roche-Lestienne V Soenen-Cornu N Grardel-Duflos Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 2002 1014 1018
46. CL Sawyers Research on resistance to cancer drug Gleevec Science 294 2001 1834
47. SR Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog Embo J 16 1997 5572 5581
48. K Parang JH Till AJ Ablooglu Mechanism-based design of a protein kinase inhibitor Nat Struct Biol 8 2001 37 41
49. JH Till AJ Ablooglu M Frankel Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism J Biol Chem 276 2001 10049 10055
50. CW Muller GJ Schlauderer J Reinstein GE Schulz Adenylate kinase motions during catalysis: an energetic counterweight balancing substrate binding Structure 4 1996 147 156
51. N Shah J Nicoll B Nagar Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117
52. AS Corbin E Buchdunger F Pascal BJ Druker Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571 J Biol Chem 277 2002 32214 32219
53. C Gambacorti-Passerini M Zucchetti D Russo Alpha 1 acid glycoprotein (AGP) binds to STI571 and substantially alters its pharmacokinetics in chronic nyeloid leukemia patients Clin Cancer Res 9 2003 in press.
54. J Ford STI571 investigators' brochure 2001 Novartis AG Basel
55. C Gambacorti-Passerini G Corneo M D'Incalci Roots of clinical resistance to STI-571 cancer therapy Science 293 2001 2163
56. C Gambacorti-Passerini Decrease of resistance to imatinib in leukaemia Lancet 359 2002 1776 1777
57. J Larghero F Mahon I Madalaine-Chambrin Elevated 1 evels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevec (STI571, imatinib) in vitro and are associated with primary resistance in vivo Blood 98 2001 2582 (abstr 616)
58. P le Coutre K Kreuzer I Na Determination of -1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571 Blood Cells Mol Dis 28 2002 75 85
59. C Gambacorti-Passerini R Barni P le Coutre Role of alpha 1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571 J Natl Cancer Inst 92 2000 1641 1650
60. JD Griffin Resistance to targeted therapy in leukaemia Lancet 359 2002 458 459
61. WK Hofmann LC Jones NA Lemp Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 99 2002 1860 1862